Sanofi, Verily Life Sciences create new JV to develop diabetes management platform

Based in Cambridge of Massachusetts, the new company will develop new comprehensive solutions which will include devices, software, medicine and professional care for diabetes management.

The new JV will use Verily’s experience in miniaturized electronics, analytics,and consumer software development, as well as Sanofi’s clinical expertise to develop novel treatments for diabetes patients.

Initially, the new firm intends to develop solutions for type 2 diabetes patients, which will help them to manage health in day to day life.

Later, the company will also focus on the development of solutions for the type 1 diabetes community, which will help them to prevent the onset of the disease.

Northern California’s Sutter Health and Western Pennsylvania’s Allegheny Health Network have collaborated with Verily and Onduo to test the new platform with healthcare professionals and people with type 2 diabetes in a clinical care setting.

Dr Joshua Riff , who previously worked for health services firm Optum, has been appointed as the CEO for the new company.

Riff said: “From monitoring food intake to testing glucose levels to actively seeking medical care, the challenges both on the physical and mental well-being of a person living with diabetes are incredibly difficult.

“We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome.”

Sanofi global diabetes and cardiovascular business unit head executive vice president Peter Guenter said: “The integration of multiple interventions, such as data-driven patient support and devices in addition to treatment, can help improve outcomes, which is important from the perspective of patients, healthcare professionals and the overall healthcare system.”

Image: Dr Joshua Riff is the CEO of Onduo. Photo: courtesy of Sanofi.